Published in Vaccine Weekly, May 28th, 2003
"A central problem for the development of DNA vaccines has been to identify immunogens capable of raising high titer, long lasting, neutralizing antibody to surface viral glycoproteins," noted T. Ross, East Carolina University, and colleagues there and at the Dana-Farber Cancer Institute in a presentation to the 10th conference on Retroviruses and Opportunistic Infections.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly